Omega-3 處方藥市場、機會、成長動力、產業趨勢分析與預測，2024-2032 年

全球 Omega-3 處方藥市場價值約 14 億美元。預測顯示，從2024 年到2032 年，複合年成長率為8.2%。而成，主要用於治療或管理心血管等疾病疾病、代謝障礙、某些發炎或神經系統問題。

心血管疾病盛行率的上昇在很大程度上推動了市場的成長。世界心臟聯盟 (WHF) 的一份報告強調，2021 年全球心血管疾病 (CVD) 死亡人數達到 2050 萬人。 CVD 成為 2021 年全球主要死因，其中 80% 的死亡發生在 CVD 上，令人震驚低收入和中等收入國家(LMIC)。這些統計數據強調了對 omega-3 處方藥等有效治療方法的迫切需求，以管理心血管疾病並改善全球健康。

研究與發展 (R&D) 的進步正在放大 omega-3 處方藥的治療潛力並擴大其應用。純化和配方技術的創新正在生產高濃度的 omega-3 製劑，具有增強的生物利用度和功效。這些進步旨在充分利用二十碳五烯酸 (EPA) 和二十二碳六烯酸 (DHA) 的治療功效，同時減少潛在的副作用。此外，正在進行的研究正在深入研究 omega-3 處方藥的其他治療途徑，其範圍不僅限於心血管健康。探索領域包括神經系統疾病、代謝障礙和發炎性疾病，以及評估 omega-3 治療阿茲海默症、類風濕性關節炎和糖尿病的臨床試驗。

全球 Omega-3 處方藥產業根據藥物類型、應用、配銷通路和地區進行分類。

市面上將藥物類型分為vascepa、lovaza等。預測顯示，到 2032 年，Vascepa 市場的銷售額將達到 13 億美元。 Vascepa 是一種高度濃縮和精製的配方，含有純二十碳五烯酸 (EPA)。這種高純度保證了 EPA 的有效劑量，不含純度較低的 omega-3 補充劑中的常見污染物，從而增強了其功效。臨床證據強調了Vascepa 的實力：正如REDUCE-IT 試驗等研究所強調的那樣，它不僅可以有效抑制三酸甘油酯水平升高（主要心血管疾病危險因子），而且還可以顯著降低主要心血管事件的風險。

到 2032 年，美國 omega-3 處方藥市場預計將達到 11 億美元。這種嚴格的監管增強了消費者信心，推動了市場成長。此外，糖尿病發病率的飆昇在這一市場擴張中發揮關鍵作用。加拿大公共衛生局的數據顯示，2021 年，約 9.4% 的人口（即 370 萬人）被診斷為糖尿病，其中男性盛行率為 10%，女性盛行率為 8.7%。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 心血管疾病盛行率上升
    • 人們對健康益處的認知不斷增強
    • 研究與開發的進步
    • 老年人口不斷增加
  • 產業陷阱與挑戰
    • 與 omega-3 藥物相關的高成本
    • 潛在的副作用
• 成長潛力分析
• 監管環境
• 技術景觀
  • 核心技術
  • 鄰近技術
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按藥物類型，2021 - 2032

• 主要趨勢
• 瓦塞帕
• 洛瓦札
• 其他藥物類型

第 6 章：市場估計與預測：按應用分類，2021 - 2032

• 主要趨勢
• 心血管疾病
• 糖尿病
• 神經系統疾病
• 其他應用

第 7 章：市場估計與預測：按配銷通路，2021 - 2032 年

• 主要趨勢
• 醫院藥房
• 零售藥房
• 網路藥房

第 8 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• AstraZeneca plc
• Amarin Corporation plc
• Camber Pharmaceuticals, Inc.
• Dr. Reddy's Laboratories Ltd.
• GSK plc
• Grupo Ferrer Internacional, S.A.
• Hikma Pharmaceuticals PLC
• Natco Pharma Limited
• Pfizer Inc.
• Viatris Inc.
• Zydus Lifesciences Limited

The Global Omega-3 Prescription Drugs Market was valued at approximately USD 1.4 billion. Projections indicate a growth rate of 8.2% CAGR from 2024 to 2032. These drugs, formulated with highly purified omega-3 fatty acids like eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are primarily used to treat or manage conditions such as cardiovascular diseases, metabolic disorders, and certain inflammatory or neurological issues.

The market growth is significantly driven by the rising prevalence of cardiovascular diseases. A report from the World Heart Federation (WHF) highlighted that the global deaths from cardiovascular disease (CVD) reached 20.5 million in 2021. CVD topped the list as the leading cause of death worldwide in 2021, with a staggering 80% of these fatalities occurring in low- and middle-income countries (LMICs). Such statistics emphasize the urgent demand for effective treatments, like omega-3 prescription drugs, to manage cardiovascular conditions and enhance global health outcomes.

Research and development (R&D) advancements are amplifying the therapeutic potential of omega-3 prescription drugs and broadening their applications. Innovations in purification and formulation technologies are yielding highly concentrated omega-3 preparations, boasting enhanced bioavailability and efficacy. These advancements aim to harness the full therapeutic benefits of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) while curtailing potential side effects. Furthermore, ongoing research is delving into additional therapeutic avenues for omega-3 prescription drugs, venturing beyond cardiovascular health. Areas of exploration include neurological conditions, metabolic disorders, and inflammatory diseases, with clinical trials evaluating omega-3s for managing Alzheimer's disease, rheumatoid arthritis, and diabetes.

The Global Omega-3 Prescription Drugs Industry is classified based on drug type, application, distribution channel and region.

The market categorizes drug types into vascepa, lovaza, and others. Projections suggest the vascepa segment will hit USD 1.3 billion by 2032. Vascepa, a highly concentrated and refined formulation, boasts pure eicosapentaenoic acid (EPA). This high purity guarantees a potent dose of EPA, free from common contaminants in lesser purified omega-3 supplements, thereby amplifying its effectiveness. Clinical evidence underscores Vascepa's prowess: it's not only effective in curbing elevated triglyceride levels-a primary cardiovascular disease risk factor-but also significantly diminishes the risk of major cardiovascular events, as highlighted in studies like the REDUCE-IT trial.

The U.S. omega-3 prescription drugs market is on track to reach USD 1.1 billion by 2032. The U.S. Food and Drug Administration (FDA) enforces stringent oversight and approval processes for these drugs, ensuring they uphold high safety, efficacy, and quality standards. Such regulatory rigor bolsters consumer confidence, fueling market growth. Additionally, the surging incidence of diabetes plays a pivotal role in this market expansion. Data from the Public Health Agency of Canada reveals that in 2021, about 9.4% of the population-translating to 3.7 million individuals-were diagnosed with diabetes, with male prevalence at 10% and female at 8.7%.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of cardiovascular diseases
    • 3.2.1.2 Growing awareness of health benefits
    • 3.2.1.3 Advancements in research and development
    • 3.2.1.4 Rising geriatric population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High costs associated with omega-3 drugs
    • 3.2.2.2 Potential side effects
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Pipeline analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Vascepa
• 5.3 Lovaza
• 5.4 Other drug types

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Cardiovascular diseases
• 6.3 Diabetes
• 6.4 Neurological disorders
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AstraZeneca plc
• 9.2 Amarin Corporation plc
• 9.3 Camber Pharmaceuticals, Inc.
• 9.4 Dr. Reddy's Laboratories Ltd.
• 9.5 GSK plc
• 9.6 Grupo Ferrer Internacional, S.A.
• 9.7 Hikma Pharmaceuticals PLC
• 9.8 Natco Pharma Limited
• 9.9 Pfizer Inc.
• 9.10 Viatris Inc.
• 9.11 Zydus Lifesciences Limited